CFFP
REGN icon

Center for Financial Planning’s Regeneron Pharmaceuticals REGN Stock Holding History

Center for Financial Planning’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3
Closed -$2.32K – 680
2026
Q1 		$2.32K Buy
+3
New +$2.3K ﹤0.01% 573
2024
Q3 		– Sell
-10
Closed -$10.5K – 598
2024
Q2 		$10.5K Hold
10
– – ﹤0.01% 392
2024
Q1 		$9.63K Hold
10
– – ﹤0.01% 410
2023
Q4 		$8.78K Hold
10
– – ﹤0.01% 382
2023
Q3 		$8.23K Hold
10
– – ﹤0.01% 376
2023
Q2 		$7.19K Hold
10
– – ﹤0.01% 418
2023
Q1 		$8.22K Hold
10
– – ﹤0.01% 379
2022
Q4 		$7.21K Hold
10
– – ﹤0.01% 387
2022
Q3 		$7K Sell
10
-1
-9% -$629 ﹤0.01% 394
2022
Q2 		$7K Buy
11
+10
+1,000% +$6.5K ﹤0.01% 399
2022
Q1 		$1K Hold
1
– – ﹤0.01% 517
2021
Q4 		$1K Buy
+1
New +$615 ﹤0.01% 523
2020
Q2 		– Sell
-10
Closed -$5K – 540
2020
Q1 		$5K Buy
+10
New +$4.13K ﹤0.01% 416

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Center for Financial Planning's REGN Position: Q2 2026 in Review

Center for Financial Planning sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 3 shares — an estimated $2.32K sold.

Center for Financial Planning first reported a position in REGN in Q1 2020 and held it in 13 quarters. The position peaked at $10.5K in Q2 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Center for Financial Planning reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Center for Financial Planning sold 3 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $2.32K.
  • Center for Financial Planning first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 13 quarters.
  • Center for Financial Planning's Regeneron Pharmaceuticals position peaked at $10.5K in Q2 2024.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Center for Financial Planning's 13F filing for Q2 2026, filed 21 Jul 2026.